Navigation Links
IDRI Announces Appointment of H. Stewart Parker as Chief Executive Officer
Date:2/15/2011

SEATTLE, Feb. 15, 2011 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) announces today the appointment of H. Stewart Parker as its new Chief Executive Officer and new member of the IDRI board of directors.  Parker is a widely recognized figure in the biotechnology industry, having served as President and CEO of Targeted Genetics Corp. and, formerly, Vice President, Corporate Development at Immunex Corp.

"I look forward to working with Stewart, who represents a balance of entrepreneurial spirit and operational expertise," said Steve Reed, IDRI's Founder and Head of Research and Development.

"I couldn't be more thrilled to join IDRI.  The organization possesses a number of technologies that may have an enormous impact on the health of the world," indicated Parker.  "To support their innovation, IDRI possesses developmental capabilities that are rare in non-profits ― yet urgently needed if global health funding is going to result in products that make a difference."  

Currently a Commercialization Consultant with the Washington Biotechnology & Biomedical Association (WBBA), Parker sits on a number of boards including OncoGenex and C3 Jian Inc. Parker was a long-term board member of Biotechnology Industry Organization (BIO).  She earned an MBA from the University of Washington Foster School of Business.  

"The board conducted an exhaustive international search as we sought the best candidate to lead IDRI," says Franklyn Prendergast, M.D., Ph.D. "Stewart's strength and status as a highly respected CEO made her a unique fit with IDRI's team, as well as with our core values and mission."

The appointment follows the announcement of several new grants that ensures IDRI's continuing success in the area of vaccine development, drug discovery, and diagnostics.

About IDRI – Translating science into global health solutions

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities — including early stage drug discovery, preclinical testing, manufacturing, and clinical trials — IDRI strives to create an efficient pathway bringing scientific innovation from the laboratory to the people who need it most.

For more information, go to www.idri.org.


'/>"/>
SOURCE Infectious Disease Research Institute (IDRI)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lab-on-a-Chip - ICAP Ocean Tomo Announces Auction of Patents for Advanced Techniques in Bio-Organic Analysis and Synthesis
2. Core Informatics Announces Second Office Location in Cambridge Massachusetts
3. RadQual, LLC Announces a New Industry Leading Dose Calibrator Reference Standard
4. Genesis Biopharma Announces Management and Board Changes
5. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
6. Orexigen® Therapeutics Announces Corporate Realignment
7. Talecris Biotherapeutics Announces Teleconference and Webcast Information for Special Meeting of Shareholders
8. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
9. Stem Cell Assurance Announces Engagement of Marcum LLP as its Independent Auditors
10. Pancreatic Cancer Action Network Announces New Initiative to Double the Survival Rate for Pancreatic Cancer Patients by 2020
11. Thermal Gradient Announces Breakthrough in Fast PCR Device Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots ... scientists from around the world, is pleased to announce the 2nd annual Precision ... 2017. This premier, online-only conference focused on the development and advancements in precision ...
(Date:2/22/2017)... -- Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech Ltd.) ... Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a ... traits and nutritional products, today announced their collaboration to achieve the ... China to the United States ... ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech consulting firm ... director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins brings 14 ... more than a decade with leading market research firm, GfK. He began his ...
(Date:2/21/2017)... -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage ... and restore the health of patients, intends to report operational highlights ... Thursday, March 2, 2017, and to host a conference call the ... call is as follows: U.S. (toll free): 1-888-347-5280 ... ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
Breaking Biology News(10 mins):